Monthly Archives: January 2018
P103 ROLE OF INFLIXIMAB IN THE MANAGEMENT OF IMMUNE-CHECKPOINT INHIBITORS-MEDIATED COLITIS (ICI-C)
Immune-checkpoint inhibitors (ICI) had made good success in in many cancer types for the past 5-10 years, meanwhile, ICI also lead to serious complications e.g. colitis. The management strategy involves high dose steroid with known significant side eff… Continue reading
P016 CASE SERIES: IMMUNOTHERAPY-INDUCED LYMPHOCYTIC COLITIS
Immunotherapy enhances T cell’s action on tumor cells by inhibiting T cell inactivation. However, upregulation of T cells can lead to immunotherapy-induced colitis in which lymphocytic colitis (LC) pattern has been less frequently described. We prese… Continue reading
P129 USEFULNESS OF PROSTAGLANDIN E-MAJOR URINARY METABOLITE MEASUREMENT FOR THE DIFFERENTIATION BETWEEN CHRONIC ENTEROPATHY ASSOCIATED WITH SLCO2A1 GENE (CEAS) AND CROHN’S DISEASE
Chronic enteropathy associated with SLCO2A1 gene (CEAS) is a rare intractable disease characterized by persistent anemia and hypoproteinemia due to multiple small intestinal ulcers. Recently, we identified that the disease is caused by loss-of-function… Continue reading
P015 BODY IMAGE DISSATISFACTION IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASES
Pediatric patients with inflammatory bowel diseases (IBD) are at increased risk for poor psychosocial outcomes, including body image dissatisfaction (BID). We aimed to determine the prevalence and risk factors for BID in CCFA Partners Kids & Teens cohort. Continue reading
P121 THE ROLE OF MICRORNAS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – A METANALYSIS REVIEW
Crohn’s disease (CD) and ulcerative colitis (UC) are the two major diseases that make up the inflammatory bowel disease (IBD). Studies indicate that several genes, in addition to those involved in the modulation of the immune response, are differential… Continue reading
P014 AVERAGE ANNUAL HEALTHCARE COSTS FOR PEDIATRIC AND ADULT PATIENTS WITH CROHN’S DISEASE OR ULCERATIVE COLITIS
Crohn’s disease (CD) and ulcerative colitis (UC) are costly conditions that require life-long disease management. Both conditions can first present at any age, but it is unknown how healthcare costs differ according to the age at first diagnosis. Continue reading
P113 STUDY OF THE PROTEOMIC PROFILE IN PATIENTS WITH ULCERATIVE COLITIS, ITS CORRELATION WITH DIAGNOSIS AND DISEASE ACTIVITY
Inflammatory bowel disease (IBD) comprises primarily 2 disorders: ulcerative colitis (UC) and Crohn’s disease (CD). Most biomarkers used are not disease specific, but reflect generalized inflammation. The Aim of the work is to identify plasma proteomic… Continue reading
P013 APOPTOTIC ENTEROPATHY INDUCED BY THALIDOMIDE IN A PATIENT WITH REFRACTORY UPPER AND COLONIC CROHNS’ DISEASE
Apoptotic bodies can be found to be marginally increased in untreated IBD. However, the presence of more than 6 apoptotic bodies per 10 contiguous crypts warrants further investigation. Apoptotic enteropathy (AE) has been described in different conditi… Continue reading
P101 RNA-SEQ ANALYSIS OF MOUSE MODELS OF COLITIS IDENTIFIES NOVEL MRNA AND LNCRNA TARGETS ASSOCIATED WITH HUMAN INFLAMMATORY BOWEL DISEASE
Inflammatory bowel disease (IBD) is a complex disorder that is associated with significant morbidity. While many advances have been made in the recent past with new diagnostic and therapeutic tools, a deeper understanding of its basic pathophysiology i… Continue reading
P012 ANTI-TNF DRUG ANTIBODY LEVELS CORRELATE WITH POST-SURGICAL RECURRENCE IN CROHN’S DISEASE (CD)
The prevention of the recurrence of Crohn’s disease (CD) after ileo-cecal resection remains difficult. Continue reading